




RealRate

PHARMACEUTICAL 2021

Lipocine Inc.
Rank 326 of 409

LIPOCINE®
ENHANCING HEALTH



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of Lipocine Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lipocine Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Lipocine Inc. is the variable Net Income, reducing the Economic Capital Ratio by 216% points.

The company's Economic Capital Ratio, given in the ranking table, is -386%, being 31% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	25,329
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,584
Liabilities, Non-Current	2,257
Other Assets	24
Other Compr. Net Income	0.038
Other Expenses	0.20
Other Liabilities	1,170
Other Net Income	-2,968
Property and Equipment	0
Research and Development	9,748
Revenues	0
Selling, General and Administrative Expense	8,248

Output Variable	Value in 1000 USD
Assets	25,353
Liabilities	10,011
Expenses	17,996
Stockholders Equity	15,342
Net Income	-20,965
Comprehensive Net Income	-20,965
Economic Capital Ratio	-386%